Selvigaltin (GB1211), an orally out there small molecule galectin-3 inhibitor designed as being a cure for liver fibrosis and cirrhosis, was evaluated to evaluate the impact of hepatic impairment on its pharmacokinetics and basic safety to deal with regulatory needs. Inhibition of galectin-three with GB1211 was not associated with any https://gb121179123.bloggip.com/39474999/5-easy-facts-about-selvigaltin-gb1211-described